Perioperative Anemia: Prevention, Diagnosis, and Management Throughout the Spectrum of Perioperative Care

Anesthesia and Analgesia

Volumn 130, Issue 5, 2020, Pages 1364-1380

  Warner, Matthew A ^a,b   Shore Lesserson, Linda ^b,c   Shander, Aryeh ^b,d   Patel, Sephalie Y ^b,e   Perelman, Seth I ^b,f   Guinn, Nicole R ^b,g  

^a MAYO CLINIC   (United States)

^b American Society of Anesthesiologists   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^d ENGLEWOOD HOSPITAL AND MEDICAL CENTER   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; IRON;

ANEMIA; BLOOD; DISEASE MANAGEMENT; ERYTHROCYTE TRANSFUSION; HUMAN; PERIOPERATIVE PERIOD; PROCEDURES;

ANEMIA; DISEASE MANAGEMENT; ERYTHROCYTE TRANSFUSION; HEMATINICS; HUMANS; IRON; PERIOPERATIVE CARE;

EID: 85083546332     PISSN: 00032999     EISSN: 15267598     Source Type: Journal    
DOI: 10.1213/ANE.0000000000004727     Document Type: Review

References (150)

1. Shander A, Hofmann A, Ozawa S, Theusinger OM, Gombotz H, Spahn DR,. Activity-based costs of blood transfusions in surgical patients at four hospitals. Transfusion. 2010; 50: 753-765.
2. Vincent JL, Baron JF, Reinhart K,; ABC (Anemia and Blood Transfusion in Critical Care) Investigators. Anemia and blood transfusion in critically ill patients. JAMA. 2002; 288: 1499-1507.
3. Hébert PC, Wells G, Blajchman MA,. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med. 1999; 340: 409-417.
4. Carson JL, Terrin ML, Noveck H,; FOCUS Investigators. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med. 2011; 365: 2453-2462.
5. Villanueva C, Colomo A, Bosch A,. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013; 368: 11-21.
6. Murphy GJ, Pike K, Rogers CA,; TITRe2 Investigators. Liberal or restrictive transfusion after cardiac surgery. N Engl J Med. 2015; 372: 997-1008.
7. Hajjar LA, Vincent JL, Galas FR,. Transfusion requirements after cardiac surgery: The TRACS randomized controlled trial. JAMA. 2010; 304: 1559-1567.
8. Fowler AJ, Ahmad T, Phull MK, Allard S, Gillies MA, Pearse RM,. Meta-analysis of the association between preoperative anaemia and mortality after surgery. Br J Surg. 2015; 102: 1314-1324.
9. Ranucci M, Di Dedda U, Castelvecchio S, Menicanti L, Frigiola A, Pelissero G,; Surgical and Clinical Outcome Research (SCORE) Group. Impact of preoperative anemia on outcome in adult cardiac surgery: A propensity-matched analysis. Ann Thorac Surg. 2012; 94: 1134-1141.
10. Shander A, Knight K, Thurer R, Adamson J, Spence R,. Prevalence and outcomes of anemia in surgery: A systematic review of the literature. Am J Med. 2004; 116 suppl 7A 58S-69S.
11. Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC,. Prevalence of anemia in persons 65 years and older in the United States: Evidence for a high rate of unexplained anemia. Blood. 2004; 104: 2263-2268.
12. Karkouti K, Wijeysundera DN, Beattie WS,; Reducing Bleeding in Cardiac Surgery (RBC) Investigators. Risk associated with preoperative anemia in cardiac surgery: A multicenter cohort study. Circulation. 2008; 117: 478-484.
13. Herzog CA, Muster HA, Li S, Collins AJ,. Impact of congestive heart failure, chronic kidney disease, and anemia on survival in the Medicare population. J Card Fail. 2004; 10: 467-472.
14. Rosencher N, Kerkkamp HE, Macheras G,; OSTHEO Investigation. Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: Blood management in elective knee and hip arthroplasty in Europe. Transfusion. 2003; 43: 459-469.
15. Lu M, Sing DC, Kuo AC, Hansen EN,. Preoperative anemia independently predicts 30-day complications after aseptic and septic revision total joint arthroplasty. J Arthroplasty. 2017; 32: S197-S201.
16. Ferraris VA, Brown JR, Despotis GJ,; Society of Thoracic Surgeons Blood Conservation Guideline Task Force. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg. 2011; 91: 944-982.
17. Mueller MM, Van Remoortel H, Meybohm P,; ICC PBM Frankfurt 2018 Group. Patient blood management: Recommendations from the 2018 Frankfurt consensus conference. JAMA. 2019; 321: 983-997.
18. Nelson DP, King CE, Dodd SL, Schumacker PT, Cain SM,. Systemic and intestinal limits of O2 extraction in the dog. J Appl Physiol (1985). 1987; 63: 387-394.
19. Gutierrez G, Reines HD, Wulf-Gutierrez ME,. Clinical review: Hemorrhagic shock. Crit Care. 2004; 8: 373-381.
20. Will ND, Kor DJ, Frank RD,. Initial postoperative hemoglobin values and clinical outcomes in transfused patients undergoing noncardiac surgery. Anesth Analg. 2019; 129: 819-829.
21. WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. 2011; Geneva, Switzerland: World Health Organization,. Available at: Http://www.who.int/vmnis/indicators/haemoglobin.pdf. Accessed October 29, 2019.
22. Nissenson AR, Goodnough LT, Dubois RW,. Anemia: Not just an innocent bystander? Arch Intern Med. 2003; 163: 1400-1404.
23. Shander A, Javidroozi M, Ozawa S, Hare GM,. What is really dangerous: Anaemia or transfusion? Br J Anaesth. 2011; 107 suppl 1 i41-i59.
24. Loor G, Rajeswaran J, Li L,. The least of 3 evils: Exposure to red blood cell transfusion, anemia, or both? J Thorac Cardiovasc Surg. 2013; 146: 1480.e6-1487.e6.
25. Shehata N, Mistry N, da Costa BR,. Restrictive compared with liberal red cell transfusion strategies in cardiac surgery: A meta-analysis. Eur Heart J. 2019; 40: 1081-1088.
26. Shander A, Kim TY, Goodnough LT,. Thresholds, triggers or requirements-time to look beyond the transfusion trials. J Thorac Dis. 2018; 10: 1152-1157.
27. Shander A, Goodnough LT,. From tolerating anemia to treating anemia. Ann Intern Med. 2019; 170: 125-126.
28. Calcaterra D, Ricci M, Shander A,. "Permissive anemia." J Card Surg. 2019; 34: 1147-1149.
29. Nemeth E, Ganz T,. Anemia of inflammation. Hematol Oncol Clin North Am. 2014; 28: 671, vi-81, vi.
30. Girelli D, Nemeth E, Swinkels DW,. Hepcidin in the diagnosis of iron disorders. Blood. 2016; 127: 2809-2813.
31. Corwin HL, Krantz SB,. Anemia of the critically ill: "acute" anemia of chronic disease. Crit Care Med. 2000; 28: 3098-3099.
32. Koch CG, Li L, Sun Z,. Hospital-acquired anemia: Prevalence, outcomes, and healthcare implications. J Hosp Med. 2013; 8: 506-512.
33. Levi M,. Twenty-five million liters of blood into the sewer. J Thromb Haemost. 2014; 12: 1592.
34. Whitehead NS, Williams LO, Meleth S,. Interventions to prevent iatrogenic anemia: A Laboratory Medicine Best Practices systematic review. Crit Care. 2019; 23: 278.
35. Goodnough LT, Maniatis A, Earnshaw P,. Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. Br J Anaesth. 2011; 106: 13-22.
36. Shander A, Goodnough LT, Javidroozi M,. Iron deficiency anemia-bridging the knowledge and practice gap. Transfus Med Rev. 2014; 28: 156-166.
37. Spahn DR, Schoenrath F, Spahn GH,. Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery: A prospective randomised trial. Lancet. 2019; 393: 2201-2212.
38. Stammers AH, Tesdahl EA, Mongero LB, Stasko A,. Gender and intraoperative blood transfusion: Analysis of 54,122 non-reoperative coronary revascularization procedures. Perfusion. 2019; 34: 236-245.
39. Sweitzer BJ,. Preoperative Assessment and Management. 2018. 3rd ed. Philadelphia, PA: Wolters Kluwer.
40. Goodnough LT, Nemeth E, Ganz T,. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood. 2010; 116: 4754-4761.
41. Urrechaga E, Hoffmann JJML, Bernal A, Arévalo JA, Cabriada JL,. Reticulocyte hemoglobin content (MCHr) in the assessment of iron deficient erythropoiesis in inflammatory bowel disease. Dig Liver Dis. 2018; 50: 1178-1182.
42. Mast AE, Blinder MA, Dietzen DJ,. Reticulocyte hemoglobin content. Am J Hematol. 2008; 83: 307-310.
43. Muñoz M, Laso-Morales MJ, Gómez-Ramírez S, Cadellas M, Núñez-Matas MJ, García-Erce JA,. Pre-operative haemoglobin levels and iron status in a large multicentre cohort of patients undergoing major elective surgery. Anaesthesia. 2017; 72: 826-834.
44. Goddard AF, James MW, McIntyre AS, Scott BB,; British Society of Gastroenterology. Guidelines for the management of iron deficiency anaemia. Gut. 2011; 60: 1309-1316.
45. Radulescu S, Brookes MJ, Salgueiro P,. Luminal iron levels govern intestinal tumorigenesis after Apc loss in vivo. Cell Rep. 2012; 2: 270-282.
46. Tolkien Z, Stecher L, Mander AP, Pereira DI, Powell JJ,. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: A systematic review and meta-analysis. PLoS One. 2015; 10: E0117383.
47. Kortman GA, Boleij A, Swinkels DW, Tjalsma H,. Iron availability increases the pathogenic potential of Salmonella typhimurium and other enteric pathogens at the intestinal epithelial interface. PLoS One. 2012; 7: E29968.
48. Stoffel NU, Cercamondi CI, Brittenham G,. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: Two open-label, randomised controlled trials. Lancet Haematol. 2017; 4: E524-e533.
49. Muñoz M, Acheson AG, Auerbach M,. International consensus statement on the peri-operative management of anaemia and iron deficiency. Anaesthesia. 2017; 72: 233-247.
50. Muñoz M, Gómez-Ramírez S, Bhandari S,. The safety of available treatment options for iron-deficiency anemia. Expert Opin Drug Saf. 2018; 17: 149-159.
51. Auerbach M, Al Talib K,. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease. Kidney Int. 2008; 73: 528-530.
52. Bhandari S,. Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice. Ther Clin Risk Manag. 2011; 7: 501-509.
53. Bolton-Maggs PH, Cohen H,. Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety. Br J Haematol. 2013; 163: 303-314.
54. Szebeni J, Fishbane S, Hedenus M,. Hypersensitivity to intravenous iron: Classification, terminology, mechanisms and management. Br J Pharmacol. 2015; 172: 5025-5036.
55. Fishbane S, Ungureanu VD, Maesaka JK, Kaupke CJ, Lim V, Wish J,. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis. 1996; 28: 529-534.
56. Gómez-Ramírez S, Shander A, Spahn DR,. Prevention and management of acute reactions to intravenous iron in surgical patients. Blood Transfus. 2019; 17: 137-145.
57. Auerbach M, Adamson JW,. How we diagnose and treat iron deficiency anemia. Am J Hematol. 2016; 91: 31-38.
58. Avni T, Bieber A, Grossman A, Green H, Leibovici L, Gafter-Gvili A,. The safety of intravenous iron preparations: Systematic review and meta-analysis. Mayo Clin Proc. 2015; 90: 12-23.
59. Ganzoni AM,. [Intravenous iron-dextran: Therapeutic and experimental possibilities]. Schweiz Med Wochenschr. 1970; 100: 301-303.
60. Auerbach M, Deloughery T,. Single-dose intravenous iron for iron deficiency: A new paradigm. Hematol Am Soc Hematol Educ Program. 2016; 2016: 57-66.
61. Goodnough LT, Skikne B, Brugnara C,. Erythropoietin, iron, and erythropoiesis. Blood. 2000; 96: 823-833.
62. Jelkmann W,. Control of erythropoietin gene expression and its use in medicine. Methods Enzymol. 2007; 435: 179-197.
63. Aapro M, Gascón P, Patel K,. Erythropoiesis-stimulating agents in the management of anemia in chronic kidney disease or cancer: A historical perspective. Front Pharmacol. 2018; 9: 1498.
64. Goel R, Patel EU, Cushing MM,. Association of perioperative red blood cell transfusions with venous thromboembolism in a north american registry. JAMA Surg. 2018; 153: 826-833.
65. Besarab A, Bolton WK, Browne JK,. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339: 584-590.
66. Strippoli GF, Craig JC, Manno C, Schena FP,. Hemoglobin targets for the anemia of chronic kidney disease: A meta-analysis of randomized, controlled trials. J Am Soc Nephrol. 2004; 15: 3154-3165.
67. Parfrey PS,. Target hemoglobin level for EPO therapy in CKD. Am J Kidney Dis. 2006; 47: 171-173.
68. Phrommintikul A, Haas SJ, Elsik M, Krum H,. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis. Lancet. 2007; 369: 381-388.
69. Pfeffer MA, Burdmann EA, Chen CY,; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361: 2019-2032.
70. Palmer SC, Navaneethan SD, Craig JC,. Meta-analysis: Erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010; 153: 23-33.
71. Tonia T, Mettler A, Robert N,. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012; 12: CD003407.
72. Aapro M, Osterwalder B, Scherhag A, Burger HU,. Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: The impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events. Br J Cancer. 2009; 101: 1961-1971.
73. Aapro M, Scherhag A, Burger HU,. Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: An updated meta-analysis of 12 randomised controlled studies including 2301 patients. Br J Cancer. 2008; 99: 14-22.
74. Stowell CP, Jones SC, Enny C, Langholff W, Leitz G,. An open-label, randomized, parallel-group study of perioperative epoetin alfa versus standard of care for blood conservation in major elective spinal surgery: Safety analysis. Spine (Phila Pa 1976). 2009; 34: 2479-2485.
75. Bedair H, Yang J, Dwyer MK, McCarthy JC,. Preoperative erythropoietin alpha reduces postoperative transfusions in THA and TKA but may not be cost-effective. Clin Orthop Relat Res. 2015; 473: 590-596.
76. Faris PM, Ritter MA, Abels RI,. The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopaedic operation. The American Erythropoietin Study Group. J Bone Joint Surg Am. 1996; 78: 62-72.
77. Feagan BG, Wong CJ, Kirkley A,. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial. Ann Intern Med. 2000; 133: 845-854.
78. Laupacis A, Feagan B, Wong C,. Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. COPES Study Group. Lancet. 1993; 342: 378.
79. Na HS, Shin SY, Hwang JY, Jeon YT, Kim CS, Do SH,. Effects of intravenous iron combined with low-dose recombinant human erythropoietin on transfusion requirements in iron-deficient patients undergoing bilateral total knee replacement arthroplasty. Transfusion. 2011; 51: 118-124.
80. So-Osman C, Nelissen RG, Koopman-van Gemert AW,. Patient blood management in elective total hip-and knee-replacement surgery (Part 1): A randomized controlled trial on erythropoietin and blood salvage as transfusion alternatives using a restrictive transfusion policy in erythropoietin-eligible patients. Anesthesiology. 2014; 120: 839-851.
81. Weber EW, Slappendel R, Hémon Y,. Effects of epoetin alfa on blood transfusions and postoperative recovery in orthopaedic surgery: The European Epoetin Alfa Surgery Trial (EEST). Eur J Anaesthesiol. 2005; 22: 249-257.
82. Weltert L, Rondinelli B, Bello R,. A single dose of erythropoietin reduces perioperative transfusions in cardiac surgery: Results of a prospective single-blind randomized controlled trial. Transfusion. 2015; 55: 1644-1654.
83. Weltert L, D'Alessandro S, Nardella S,. Preoperative very short-term, high-dose erythropoietin administration diminishes blood transfusion rate in off-pump coronary artery bypass: A randomized blind controlled study. J Thorac Cardiovasc Surg. 2010; 139: 621-626.
84. Yoo YC, Shim JK, Kim JC, Jo YY, Lee JH, Kwak YL,. Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery. Anesthesiology. 2011; 115: 929-937.
85. Larson B, Bremme K, Clyne N, Nordström L,. Preoperative treatment of anemic women with epoetin beta. Acta Obstet Gynecol Scand. 2001; 80: 559-562.
86. Dousias V, Paraskevaidis E, Dalkalitsis N, Tsanadis G, Navrozoglou I, Lolis D,. Recombinant human erythropoietin in mildly anemic women before total hysterectomy. Clin Exp Obstet Gynecol. 2003; 30: 235-238.
87. Qvist N, Boesby S, Wolff B, Hansen CP,. Recombinant human erythropoietin and hemoglobin concentration at operation and during the postoperative period: Reduced need for blood transfusions in patients undergoing colorectal surgery-prospective double-blind placebo-controlled study. World J. Surg. 1999; 23: 30-35.
88. Christodoulakis M, Tsiftsis DD,; Hellenic Surgical Oncology Perioperative EPO Study Group. Preoperative epoetin alfa in colorectal surgery: A randomized, controlled study. Ann Surg Oncol. 2005; 12: 718-725.
89. Heiss MM, Tarabichi A, Delanoff C,. Perisurgical erythropoietin application in anemic patients with colorectal cancer: A double-blind randomized study. Surgery. 1996; 119: 523-527.
90. Kettelhack C, Hönes C, Messinger D, Schlag PM,. Randomized multicentre trial of the influence of recombinant human erythropoietin on intraoperative and postoperative transfusion need in anaemic patients undergoing right hemicolectomy for carcinoma. Br J Surg. 1998; 85: 63-67.
91. Kosmadakis N, Messaris E, Maris A,. Perioperative erythropoietin administration in patients with gastrointestinal tract cancer: Prospective randomized double-blind study. Ann Surg. 2003; 237: 417-421.
92. Scott SN, Boeve TJ, McCulloch TM, Fitzpatrick KA, Karnell LH,. The effects of epoetin alfa on transfusion requirements in head and neck cancer patients: A prospective, randomized, placebo-controlled study. Laryngoscope. 2002; 112: 1221-1229.
93. Wurnig C, Schatz K, Noske H,. Subcutaneous low-dose epoetin beta for the avoidance of transfusion in patients scheduled for elective surgery not eligible for autologous blood donation. Eur Surg Res. 2001; 33: 303-310.
94. Drawz P, Rahman M,. Chronic kidney disease. Ann Intern Med. 2015; 162: ITC1-IT16.
95. Sonzogni V, Crupi G, Poma R,. Erythropoietin therapy and preoperative autologous blood donation in children undergoing open heart surgery. Br J Anaesth. 2001; 87: 429-434.
96. Meara JG, Smith EM, Harshbarger RJ, Farlo JN, Matar MM, Levy ML,. Blood-conservation techniques in craniofacial surgery. Ann Plast Surg. 2005; 54: 525-529.
97. Fearon JA, Weinthal J,. The use of recombinant erythropoietin in the reduction of blood transfusion rates in craniosynostosis repair in infants and children. Plast Reconstr Surg. 2002; 109: 2190-2196.
98. Helfaer MA, Carson BS, James CS, Gates J, Della-Lana D, Vander Kolk C,. Increased hematocrit and decreased transfusion requirements in children given erythropoietin before undergoing craniofacial surgery. J Neurosurg. 1998; 88: 704-708.
99. Breymann C, Visca E, Huch R, Huch A,. Efficacy and safety of intravenously administered iron sucrose with and without adjuvant recombinant human erythropoietin for the treatment of resistant iron-deficiency anemia during pregnancy. Am J Obstet Gynecol. 2001; 184: 662-667.
100. Krafft A, Bencaiova G, Breymann C,. Selective use of recombinant human erythropoietin in pregnant patients with severe anemia or nonresponsive to iron sucrose alone. Fetal Diagn Ther. 2009; 25: 239-245.
101. Reisenberger K, Egarter C, Kapiotis S, Sternberger B, Gregor H, Husslein P,. Transfer of erythropoietin across the placenta perfused in vitro. Obstet Gynecol. 1997; 89: 738-742.
102. Devalia V, Hamilton MS, Molloy AM,; British Committee for Standards in Haematology. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. Br J Haematol. 2014; 166: 496-513.
103. Green R,. Vitamin B12 deficiency from the perspective of a practicing hematologist. Blood. 2017; 129: 2603-2611.
104. Patel MS, Carson JL,. Anemia in the preoperative patient. Med Clin North Am. 2009; 93: 1095-1104.
105. Panjeta M, Tahirović I, Sofić E, Ćorić J, Dervišević A,. Interpretation of Erythropoietin and haemoglobin levels in patients with various stages of chronic kidney disease. J Med Biochem. 2017; 36: 145-152.
106. Shander A, Javidroozi M,. Strategies to reduce the use of blood products: A US perspective. Curr Opin Anaesthesiol. 2012; 25: 50-58.
107. Barile L, Fominskiy E, Di Tomasso N,. Acute normovolemic hemodilution reduces allogeneic red blood cell transfusion in cardiac surgery: A systematic review and meta-analysis of randomized trials. Anesth Analg. 2017; 124: 743-752.
108. Zhou X, Zhang C, Wang Y, Yu L, Yan M,. Preoperative acute normovolemic hemodilution for minimizing allogeneic blood transfusion: A meta-analysis. Anesth Analg. 2015; 121: 1443-1455.
109. Carless PA, Henry DA, Moxey AJ, O'Connell D, Brown T, Fergusson DA,. Cell salvage for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2010; 4: CD001888.
110. Kumar N, Ahmed Q, Lee VK,. Can there be a place for intraoperative salvaged blood in spine tumor surgery? Ann Surg Oncol. 2014; 21: 2436-2443.
111. Goucher H, Wong CA, Patel SK, Toledo P,. Cell salvage in obstetrics. Anesth Analg. 2015; 121: 465-468.
112. Levy JH, Dutton RP, Hemphill JC III,; Hemostasis Summit Participants. Multidisciplinary approach to the challenge of hemostasis. Anesth Analg. 2010; 110: 354-364.
113. Zhang Y, Liu H, He F, Chen A, Yang H, Pi B,. Does tranexamic acid improve bleeding, transfusion, and hemoglobin level in patients undergoing multilevel spine surgery? a systematic review and meta-analysis. World Neurosurg. 2019; 127: 289-301.
114. Derzon JH, Clarke N, Alford A, Gross I, Shander A, Thurer R,. Reducing red blood cell transfusion in orthopedic and cardiac surgeries with antifibrinolytics: A laboratory medicine best practice systematic review and meta-analysis. Clin Biochem. 2019; 71: 1-13.
115. Guo J, Gao X, Ma Y,. Different dose regimes and administration methods of tranexamic acid in cardiac surgery: A meta-analysis of randomized trials. BMC Anesthesiol. 2019; 19: 129.
116. WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): An international, randomised, double-blind, placebo-controlled trial. Lancet. 2017; 389: 2105-2116.
117. Roberts I, Shakur H, Coats T,. The CRASH-2 trial: A randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess. 2013; 17: 1-79.
118. Khan M, Jehan F, Bulger EM,; PROPPR Study Group. Severely injured trauma patients with admission hyperfibrinolysis: Is there a role of tranexamic acid? Findings from the PROPPR trial. J Trauma Acute Care Surg. 2018; 85: 851-857.
119. Tran A, Yates J, Lau A, Lampron J, Matar M,. Permissive hypotension versus conventional resuscitation strategies in adult trauma patients with hemorrhagic shock: A systematic review and meta-analysis of randomized controlled trials. J Trauma Acute Care Surg. 2018; 84: 802-808.
120. Hughes MJ, Ventham NT, Harrison EM, Wigmore SJ,. Central venous pressure and liver resection: A systematic review and meta-analysis. HPB (Oxford). 2015; 17: 863-871.
121. Wikkelsø A, Wetterslev J, Møller AM, Afshari A,. Thromboelastography (TEG) or rotational thromboelastometry (ROTEM) to monitor haemostatic treatment in bleeding patients: A systematic review with meta-analysis and trial sequential analysis. Anaesthesia. 2017; 72: 519-531.
122. Dias JD, Sauaia A, Achneck HE, Hartmann J, Moore EE,. Thromboelastography-guided therapy improves patient blood management and certain clinical outcomes in elective cardiac and liver surgery and emergency resuscitation: A systematic review and analysis. J Thromb Haemost. 2019; 17: 984-994.
123. Laso-Morales MJ, Vives R, Gómez-Ramírez S, Pallisera-Lloveras A, Pontes C,. Intravenous iron administration for post-operative anaemia management after colorectal cancer surgery in clinical practice: A single-centre, retrospective study. Blood Transfus. 2018; 16: 338-342.
124. Muñoz M, Auerbach M,. Postoperative intravenous iron: A simple strategy to improve outcomes. Lancet Haematol. 2016; 3: E401-e402.
125. Khalafallah AA, Yan C, Al-Badri R,. Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: A prospective, open-label, randomised controlled trial. Lancet Haematol. 2016; 3: E415-e425.
126. Chant C, Wilson G, Friedrich JO,. Anemia, transfusion, and phlebotomy practices in critically ill patients with prolonged ICU length of stay: A cohort study. Crit Care. 2006; 10: R140.
127. Corwin HL, Gettinger A, Fabian TC,; EPO Critical Care Trials Group. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med. 2007; 357: 965-976.
128. Faraoni D, DiNardo JA, Goobie SM,. Relationship between preoperative anemia and in-hospital mortality in children undergoing noncardiac surgery. Anesth Analg. 2016; 123: 1582-1587.
129. Goobie SM, Faraoni D, Zurakowski D, DiNardo JA,. Association of preoperative anemia with postoperative mortality in neonates. JAMA Pediatr. 2016; 170: 855-862.
130. Bierer R, Roohi M, Peceny C, Ohls RK,. Erythropoietin increases reticulocyte counts and maintains hematocrit in neonates requiring surgery. J Pediatr Surg. 2009; 44: 1540-1545.
131. Crary SE, Hall K, Buchanan GR,. Intravenous iron sucrose for children with iron deficiency failing to respond to oral iron therapy. Pediatr Blood Cancer. 2011; 56: 615-619.
132. Meneghini L, Zadra N, Aneloni V, Metrangolo S, Faggin R, Giusti F,. Erythropoietin therapy and acute preoperative normovolaemic haemodilution in infants undergoing craniosynostosis surgery. Paediatr Anaesth. 2003; 13: 392-396.
133. Ludwig H, Van Belle S, Barrett-Lee P,. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004; 40: 2293-2306.
134. Busti F, Marchi G, Ugolini S, Castagna A, Girelli D,. Anemia and iron deficiency in cancer patients: Role of iron replacement therapy. Pharmaceuticals (Basel). 2018; 11: E94.
135. Huang XZ, Yang YC, Chen Y,. Preoperative anemia or low hemoglobin predicts poor prognosis in gastric cancer patients: A meta-analysis. Dis Markers. 2019; 2019: 7606128.
136. Munting KE, Klein AA,. Optimisation of pre-operative anaemia in patients before elective major surgery-why, who, when and how? Anaesthesia. 2019; 74 suppl 1 49-57.
137. Ramsey G, Lindholm PF,. Thrombosis risk in cancer patients receiving red blood cell transfusions. Semin Thromb Hemost. 2019; 45: 648-656.
138. Leyland-Jones B,. Erythropoiesis stimulating agents: A personal journey. J Natl Cancer Inst. 2013; 105: 999-1001.
139. Henke M, Laszig R, Rübe C,. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet. 2003; 362: 1255-1260.
140. Leyland-Jones B, Semiglazov V, Pawlicki M,. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol. 2005; 23: 5960-5972.
141. Wright JR, Ung YC, Julian JA,. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol. 2007; 25: 1027-1032.
142. Bohlius J, Bohlke K, Castelli R,. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. J Clin Oncol. 2019; 37: 1336-1351.
143. McCartney S, Guinn N, Roberson R, Broomer B, White W, Hill S,. Jehovah's Witnesses and cardiac surgery: A single institution's experience. Transfusion. 2014; 54: 2745-2752.
144. Pattakos G, Koch CG, Brizzio ME,. Outcome of patients who refuse transfusion after cardiac surgery: A natural experiment with severe blood conservation. Arch Intern Med. 2012; 172: 1154-1160.
145. Guinn NR, Roberson RS, White W,. Costs and outcomes after cardiac surgery in patients refusing transfusion compared with those who do not: A case-matched study. Transfusion. 2015; 55: 2791-2798.
146. Guinn NR, Cooter ML, Villalpando C, Weiskopf RB,. Severe anemia associated with increased risk of death and myocardial ischemia in patients declining blood transfusion. Transfusion. 2018; 58: 2290-2296.
147. Carson JL, Noveck H, Berlin JA, Gould SA,. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion. 2002; 42: 812-818.
148. Shander A, Javidroozi M, Naqvi S,. An update on mortality and morbidity in patients with very low postoperative hemoglobin levels who decline blood transfusion (CME). Transfusion. 2014; 54 (10 pt 2): 2688-2695.
149. Goodnough LT,. Iron deficiency syndromes and iron-restricted erythropoiesis (CME). Transfusion. 2012; 52: 1584-1592.
150. Peters F, Ellermann I, Steinbicker AU,. Intravenous iron for treatment of anemia in the 3 perisurgical phases: A review and analysis of the current literature. Anesth Analg. 2018; 126: 1268-1282.